New hope for blood cancer patients: experimental drug DZD8586 enters phase 2 trial

NCT ID NCT06539182

Recruiting now Disease control Sponsor: Dizal Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called DZD8586 (Birelentinib) in 155 adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or not responded to prior treatment. Participants take one of three daily doses to see if the drug shrinks tumors and to check for side effects. The goal is to find a new treatment option for this hard-to-treat blood cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DZD8586 (Birelentinib)
What this could lead to: If successful, this could offer a new oral treatment option for people with CLL/SLL whose cancer has returned or stopped responding to other therapies.
What could go wrong: This is a Phase 2 trial with a moderate number of participants, so results are still preliminary. The drug may cause side effects or not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Locations

First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
RECRUITING

Nanjing, Jiangsu, China
Research Site
RECRUITING

Hefei, Anhui, China
Research Site
RECRUITING

Beijing, Beijing Municipality, 100053, China
Research Site
RECRUITING

Beijing, Beijing Municipality, 100191, China
Research Site
RECRUITING

Guangzhou, Guandong, 510280, China
Research Site
RECRUITING

Guangzhou, Guandong, 510515, China
Research Site
RECRUITING

Zhengzhou, Henan, China
Research Site
RECRUITING

Wuhan, Hubei, China
Research Site
RECRUITING

Changchun, Jilin, China
Research Site
NOT_YET_RECRUITING

Dalian, Liaoning, China
Research Site
RECRUITING

Shenyang, Liaoning, China
Research Site
RECRUITING

Jinan, Shandong, China
Research Site
RECRUITING

Linyi, Shandong, China
Research Site
RECRUITING

Shanghai, Shanghai Municipality, China
Research Site
RECRUITING

Taiyuan, Shangxi, China
Research Site
RECRUITING

Tianjin, Tianjin Municipality, 300020, China
Research Site
RECRUITING

Tianjin, Tianjin Municipality, 300060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.